{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:02:30Z","timestamp":1789754550925,"version":"4.0.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006095","name":"South-Eastern Norway Regional Health Authority","doi-asserted-by":"publisher","award":["2017100"],"award-info":[{"award-number":["2017100"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008021","name":"Bristol Myers Squibb Canada Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.radonc.2026.111514","type":"journal-article","created":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T20:20:59Z","timestamp":1774815659000},"page":"111514","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Hyperfractionated reirradiation and PD-1 blockade in recurrent squamous cell head and neck carcinomas with poor prognosis, results from the REPORT-trial"],"prefix":"10.1016","volume":"219","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9095-1883","authenticated-orcid":false,"given":"Hanne Astrid","family":"Eide","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9271-8789","authenticated-orcid":false,"given":"Harald","family":"Grut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Jebsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2854-3694","authenticated-orcid":false,"given":"Jon Amund","family":"Kyte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c5se","family":"Bratland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2026.111514_b0005","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3109\/0284186X.2015.1117136","article-title":"Failure pattern and salvage treatment after radical treatment of head and neck cancer","volume":"55","author":"Pagh","year":"2016","journal-title":"Acta Oncologica"},{"key":"10.1016\/j.radonc.2026.111514_b0010","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s13014-020-01587-3","article-title":"Overlapping volumes in re-irradiation for head and neck cancer \u2013 an important factor for patient selection","volume":"15","author":"Embring","year":"2020","journal-title":"Radiat Oncol"},{"issue":"13","key":"10.1016\/j.radonc.2026.111514_b0015","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.3390\/cancers13133173","article-title":"Re-irradiation for head and neck cancer: cumulative dose to organs at risk and late side effects","volume":"13","author":"Embring","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.radonc.2026.111514_b0020","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1016\/S1470-2045(22)00447-8","article-title":"European society for radiotherapy and oncology and european organisation for research and treatment of cancer consensus on re-irradiation: definition, reporting, and clinical decision making","volume":"23","author":"Andratschke","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111514_b0025","doi-asserted-by":"crossref","unstructured":"Beddok A, Willmann J, Embring A, Appelt AL, Balermpas P, Chua K, et al. Reirradiation: Standards, challenges, and patient\u2010focused strategies across tumor types. CA A Cancer J Clinicians. May 29, 2025;caac.70016.","DOI":"10.3322\/caac.70016"},{"key":"10.1016\/j.radonc.2026.111514_b0030","doi-asserted-by":"crossref","unstructured":"Lee AM, Weaver AN, Acosta P, Harris L, Bowles DW. Review of Current and Future Medical Treatments in Head and Neck Squamous Cell Carcinoma. Cancers. October 15, 2024;16(20):3488.","DOI":"10.3390\/cancers16203488"},{"key":"10.1016\/j.radonc.2026.111514_b0035","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111514_b0040","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med January 22"},{"key":"10.1016\/j.radonc.2026.111514_b0045","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111514_b0050","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2026.111514_b0055","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2026.111514_b0060","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med November 10"},{"key":"10.1016\/j.radonc.2026.111514_b0065","doi-asserted-by":"crossref","unstructured":"Burtness B, Harrington KJ, Greil R, Souli\u00e8res D, Tahara M, De Castro G, et al. KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent\/metastatic head and neck squamous cell carcinoma (R\/M HNSCC). Annals of Oncology. October 2018;29:viii729.","DOI":"10.1093\/annonc\/mdy424.045"},{"key":"10.1016\/j.radonc.2026.111514_b0070","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.annonc.2020.07.011","article-title":"Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS\u2013ESMO\u2013ESTRO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Machiels","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2026.111514_b0075","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1080\/09553002.2019.1623429","article-title":"Radiation therapy to enhance tumor immunotherapy: a novel application for an established modality","volume":"95","author":"Ko","year":"2019","journal-title":"Int J Radiat Biol"},{"key":"10.1016\/j.radonc.2026.111514_b0080","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.semradonc.2019.12.005","article-title":"The impact of radiation therapy on innate and adaptive tumor immunity","volume":"30","author":"Brandmaier","year":"2020","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111514_b0085","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti\u2013PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J Clin Invest February 3"},{"key":"10.1016\/j.radonc.2026.111514_b0090","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1016\/S1470-2045(19)30171-8","article-title":"Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy","volume":"20","author":"Deutsch","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111514_b0095","doi-asserted-by":"crossref","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal of Cancer. January 2009;45(2):228\u2013247.","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"10.1016\/j.radonc.2026.111514_b0100","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111514_b0105","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.radonc.2026.111514_b0110","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.semradonc.2025.02.009","article-title":"Reirradiation for locally recurrent head and neck cancer: state-of-the-art and future directions","volume":"35","author":"Phan","year":"2025","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111514_b0115","article-title":"Impact of hyperfractionated re-irradiation on quality of life in patients with recurrent or second primary head and neck cancer, a prospective single institutional study","volume":"42","author":"Amdal","year":"2023","journal-title":"Clin Trans Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111514_b0120","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","article-title":"Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111514_b0125","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S1470-2045(24)00100-1","article-title":"Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial","volume":"25","author":"Machiels","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111514_b0130","article-title":"Re-irradiation with concurrent pembrolizumab for local-regionally recurrent squamous cell carcinoma of the head and neck","volume":"13","author":"Chen","year":"2025","journal-title":"Oral Oncol Rep"},{"key":"10.1016\/j.radonc.2026.111514_b0135","first-page":"71","article-title":"Re-irradiation with concurrent and maintenance nivolumab in locally recurrent and inoperable squamous cell carcinoma of the head and neck: a single-center cohort study","volume":"28","author":"Altay-Langguth","year":"2021","journal-title":"Clin Trans Radiat Oncol"},{"issue":"7","key":"10.1016\/j.radonc.2026.111514_b0140","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/jamaoncol.2024.1143","article-title":"Intensity-modulated reirradiation therapy with nivolumab in recurrent or second primary head and neck squamous cell carcinoma: a nonrandomized controlled trial","volume":"10","author":"Saba","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2026.111514_b0145","unstructured":"Tao Y, Siu LL, Licitra LF, Burtness B, Tahara M, Rischin D, et al. Long-term results of the randomized, phase 3 KEYNOTE-412 trial of pembrolizumab (pembro) or placebo (pbo) plus concurrent chemoradiotherapy (CRT) for unresected, locally advanced head and neck squamous cell carcinoma (LA HNSCC)."},{"key":"10.1016\/j.radonc.2026.111514_b0150","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111514_b0155","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.radonc.2026.111514_bib161","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1056\/NEJMoa2415434","article-title":"Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer","volume":"393","author":"Uppaluri","year":"2025","journal-title":"N Engl J Med."},{"key":"10.1016\/j.radonc.2026.111514_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110278","article-title":"Re-irradiation versus systemic therapy for the management of local-regionally recurrent head and neck cancer","volume":"196","author":"Chen","year":"2024","journal-title":"Radiother Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026001532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026001532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:05:42Z","timestamp":1789751142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814026001532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":33,"alternative-id":["S0167814026001532"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111514","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hyperfractionated reirradiation and PD-1 blockade in recurrent squamous cell head and neck carcinomas with poor prognosis, results from the REPORT-trial","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111514","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111514"}}